Micromet Presents Data at ESMO 2008 on Anti-EpCAM Antibody Adecatumumab (MT201) in Combination with Ch...( Interim data from Phase 1b Study ind...),Health

Interim data from Phase 1b Study indicate that adecatumumab in combination with docetaxel is safe and well tolerated and suggest a better outcome for

breast cancer patients with high EpCAM expression

BETHESDA, Md., Sept. 15 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, presented interim data from a study investigating its anti-EpCAM antibody adecatumumab (MT201) in combination with the chemotherapeutic docetaxel(1) on Saturday, September 13 at the 2008 meeting of the European Society of Medical Oncology (ESMO) held in Stockholm, Sweden.

Adecatumumab is an antibody that targets EpCAM, a tumor antigen known to be associated with poor prognosis for many solid cancers. A previous phase 2 trial investigating adecatumumab as a single agent in patients with metastatic breast cancer (MBC) suggested that treatment with adecatumumab was associated with fewer new metastases in patients with high EpCAM expression compared to patients with low EpCAM expression(2).

The ongoing phase 1b clinical trial presented at ESMO investigated the safety and tolerability of increasing doses of adecatumumab in combination with standard chemotherapy docetaxel in relapsed MBC patients who had a median of three prior chemotherapy regimens. Combining adecatumumab with docetaxel appears to be feasible with clinically manageable diarrhea being the main toxicity at higher doses. Other frequently observed adverse events included nausea, vomiting, stomatitis, constipation, fatigue, fever and chills. No increase in adverse events or laboratory abnormalities typically seen with docetaxel was observe
'/>"/>